<DOC>
	<DOCNO>NCT00647868</DOCNO>
	<brief_summary>In study serum concentration testosterone main metabolite DHT measure hypogonadal men use intranasal testosterone ( Nasobol ) . Different treatment regimen ( twice daily ) administration time test . The serum level obtain compare healthy men . It expect intranasal administration Nasobol restore testosterone DHT level nearly normal .</brief_summary>
	<brief_title>NASOBOL Hypogonadal Men Comparison Testosterone Levels Normal Healthy Male Volunteers</brief_title>
	<detailed_description>This pharmacokinetic trial perform aim determine pharmacokinetic behavior testosterone repeat nasal administration NASOBOL® patient hypogonadism compare level major analytes level see normal healthy men . For purpose , four different treatment schedule administration NASOBOL® test compare 24-h level normal healthy men . This Phase II , pharmacokinetic trial different administration scheme NASOBOL® patient moderate hypogonadism ( Groups 1 , 2 3 ) . For reference purpose frequent blood sample take group healthy men ( Group 4 ) . Subjects screen eligibility 4 week 1st dose NASOBOL® . Total study duration hypogonadal patient maximally 38 day ( include 3 day placebo run-in phase ) . Healthy men screen eligibility clinic 1 day ( overnight stay ) study . For hypogonadal patient 7 visit clinic plan , amongst 2 visit 24-h PK sampling overnight stay . Seven day last dose NASOBOL® hypogonadal patient ask come clinic final follow-up visit . Telephone follow-ups do Days 7 , 13 , 21 27 check whether subject take medication .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Inclusion Criteria hypogonadal subject : men primary secondary hypogonadism testosterone serum level 300 ng/dl [ = 10.4 nmol/l ] , two occasion within period one month inclusion ; age : 2060 year ; normal thyroid function , physiologic prolactin concentration ; normal otorhinolaryngologic examination ( ENT examination ) ; normal 24h activityrest pattern ; write Informed Consent . Exclusion Criteria hypogonadal subject : significant intercurrent disease type , particular liver , kidney heart disease , form diabetes mellitus psychiatric illness ( patient treat hyperlipidemia , arterial hypertension treat hyper hypothyroidism exclude provide stable medication least two month ) ; history , current nasal disorder ( e.g . seasonal perennial allergic rhinitis , atrophic rhinitis , polyposis , abuse nasal decongestant , clinically relevant nasal septum deviation , recurrent epistaxis ) sleep apnea ; sleep disorder ; abnormal prostate examination indicative prostate cancer elevate serum PSA level ( PSA &lt; 2.5 ng/ml subject &lt; 40 year age &lt; 4 ng/ml subject &gt; = 40 year age ) ; history cancer , especially breast , prostate testicular tumor ; exclude skin cancer ; history severe multiple allergy , severe adverse drug reaction leucopenia . A known hypersensitivity lignocaine/lidocaine surgical dressing may use study procedure ; history abnormal bleeding tendency thrombophlebitis unrelated venepuncture intravenous cannulation , history Hepatitis B , positive test Hepatitis B surface antigen , history Hepatitis C , positive test Hepatitis C antibody , history HIV infection demonstration HIV antibody ; patient heavy smoker currently smoke &gt; 20 cigarette per day smoke history &gt; 10 pack year ( 1 pack year define 20 cigarette per day 1 year ) ; regular drinker four ( 4 ) unit alcohol daily ( 1 unit = 300 ml beer , 1 glass wine , 1 measure spirit ) may difficulty abstain alcohol 48 hour prior initialdose administration duration study ; history current evidence abuse alcohol drug substance , licit illicit ; positive urine drug alcohol screen drug abuse alcohol ; treatment androgen ( e.g . DHEA ) , anabolic steroid sex hormone within one month prior Day 1 study ; testosterone treatment previous 2 week ( oral , buccal , topical , nasal ) 4 week ( intramuscular ) ; current recent ( previous 4 week ) use counter male enhancement product ; use nasal decongestant nasal corticosteroid ; shift work ; transmeridian flight within 1 month Day 1 study ; poor compliers unlikely attend ; intake drug part research study within 30 day initialdose administration study throughout study ; blood donation within 12week period initial study dose . Inclusion criterion eugonadal subject : men testosterone serum level 300 ng/dl [ = 10.4 nmol/l ] two occasion within period one month inclusion ; age : 2060 year ; normal thyroid function , physiologic prolactin concentration ; normal 24h activityrest pattern ; write Informed Consent . Exclusion criterion eugonadal subject : significant intercurrent disease type , particular liver , kidney heart disease , form diabetes mellitus psychiatric illness ( patient treat hyperlipidemia , arterial hypertension treat hyper hypothyroidism exclude provide stable medication least two month ) ; history hypogonadism ; sleep disorder ; treatment androgen ( e.g . DHEA ) , anabolic steroid sex hormone within one month prior Day 1 study ; testosterone treatment previous 2 week ( oral , buccal , topical , nasal ) 4 week ( intramuscular ) ; current recent ( previous 4 week ) use counter male enhancement product ; shift work ; transmeridian flight within 1 month Day 1 study ; patient heavy smoker currently smoke &gt; 20 cigarette per day smoke history &gt; 10 pack year ( 1 pack year define 20 cigarette per day 1 year ) ; regular drinker four ( 4 ) unit alcohol daily ( 1 unit = 300 ml beer , 1 glass wine , 1 measure spirit ) may difficulty abstain alcohol 48 hour prior 24h blood sample day ; blood donation within 12week period 24h blood sample day .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>testosterone</keyword>
	<keyword>hypogonadism</keyword>
</DOC>